drugset / Trial / NCT06187493

Treatment of Patients With Diabetic Kidney Disease

NCT06187493

Unknown 70 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. So, this study aimed to compare the effectiveness of SGlT2i versus ACEi in the progression of diabetic kidney disease including progression of albuminuria. Doubling of serum creatinine and need for renal replacement therapy

Timeline

Start
2024-01-01
Primary completion
2025-01-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule
Subject Empagliflozin Small molecule
Subject Enalapril Other / unclassified
Subject LISINOPRIL ANHYDROUS Small molecule